Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line Sulfonylureas

Name: Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line Sulfonylureas
License: Public Domain

Boehringer Ingelheim

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

cardiovascular-diseases diabetes-mellitus type-2

diabetes mellitus, type 2, cardiovascular diseases

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 674873
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.